Novo Nordisk, Eli Lilly and diabetes drug Ozempic
Digest more
(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo Nordisk, the maker of the GLP-1 drug Ozempic, announced Monday that U.S. patients can now get a month’s supply for just under $500. It typically carries a list price of around $1,000 a month.
Novo Nordisk launches a new cash-pay option for a leading diabetes drug, changing affordability dynamics for uninsured patients across the U.S.
The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for Americans.
In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Health Canada has approved Ozempic in an effort to help reduce the risk of kidney decline for patients living with Type 2 diabetes. The decision comes after an international clinical trial found the risk of deteriorating kidney function was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection.